Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers
The low-GWP propellant, HFA-152a is expected to achieve > 90% reduction in the carbon footprint of salbutamol pMDI versus the currently used HFA-134a. The development of salbutamol pMDI with HFA-152a is a crucial step towards ensuring future patient access to salbutamol in a pMDI.
Authors
- Sourabh Fulmali
- Ashley Woodcock (ORCID: https://orcid.org/0000-0002-5428-8578)
- Christer Janson (ORCID: https://orcid.org/0000-0001-5093-6980)
- Antonio Anzueto (ORCID: https://orcid.org/0000-0002-7007-588X)
- Richard W. Henderson (ORCID: https://orcid.org/0000-0003-4509-7689)
- Maximilian Plank (ORCID: https://orcid.org/0000-0002-2111-1370)
- Alex Wilkinson (ORCID: https://orcid.org/0000-0002-1808-3663)
- James F. King (ORCID: https://orcid.org/0009-0009-2231-9745)
Institutions
- Uppsala University (SE)
- The University of Texas at San Antonio Health Science Center (US)
- University of Manchester (GB)
- Sustainability Institute (ZA)
- GlaxoSmithKline (India) (IN)
- East and North Hertfordshire NHS Trust (GB)
- South Texas Veterans Health Care System (US)
- Gold Coast Health (AU)
Publication Details
- Journal
- Allergy
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1111/all.70141
- Citations
- 1
- Primary Topic
- Pharmacological Effects and Assays
- Type
- article
- Field-Weighted Citation Impact
- 1.19